STEAP1 (six-transmembrane epithelial antigen of the prostate 1), a transmembrane channel used as ions/proteins transporter, represents an ideal target for ADC-based therapies because of its high expression in prostate cancer cells whereas it is very low expressed in normal tissues [44]. The gene discussed is STEAP1; the disease is prostate carcinoma.